Keros Therapeutics’ (KROS) Outperform Rating Reiterated at Oppenheimer

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “outperform” rating reissued by investment analysts at Oppenheimer in a research note issued on Wednesday,Benzinga reports. They presently have a $27.00 target price on the stock, up from their previous target price of $23.00. Oppenheimer’s price objective suggests a potential upside of 54.40% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Wedbush increased their price objective on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Zacks Research raised shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, HC Wainwright reduced their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Hold” and an average price target of $30.22.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $0.59 during midday trading on Wednesday, hitting $17.49. The company’s stock had a trading volume of 421,689 shares, compared to its average volume of 919,442. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The firm’s fifty day moving average price is $15.56 and its 200-day moving average price is $14.67. The firm has a market cap of $532.83 million, a P/E ratio of 11.36, a P/E/G ratio of 0.38 and a beta of 1.12.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. During the same quarter last year, the company posted ($1.41) earnings per share. Keros Therapeutics’s revenue was up 3585.6% on a year-over-year basis. As a group, research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The disclosure for this sale is available in the SEC filing. Company insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Jump Financial LLC acquired a new position in shares of Keros Therapeutics in the 1st quarter valued at approximately $1,058,000. Tejara Capital Ltd acquired a new position in Keros Therapeutics in the first quarter valued at approximately $410,000. Assenagon Asset Management S.A. lifted its holdings in shares of Keros Therapeutics by 56.0% in the second quarter. Assenagon Asset Management S.A. now owns 101,297 shares of the company’s stock valued at $1,352,000 after purchasing an additional 36,360 shares in the last quarter. Invesco Ltd. raised its position in Keros Therapeutics by 163.7% in the 1st quarter. Invesco Ltd. now owns 33,266 shares of the company’s stock valued at $339,000 after buying an additional 20,650 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after buying an additional 205,022 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.